SCHEMBL4577239

SCHEMBL4577239

Cc1coc(C(=O)O)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NOTUM Q6P988 1/20 0.38
GPR35 Q9HC97 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
EDNRA P25101 1/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
ESR1 P03372 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
APEX1 P27695 1/20 0.33
MAPK1 P28482 1/20 0.33
ESR2 Q92731 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8869893 0.85 MCL1 (0.38) MCL1MEN1KMT2AGPR35SMN1; SMN2
SCHEMBL6855931 0.81 NQO1 (0.31) SMN1; SMN2
SCHEMBL4611852 0.79 MKNK2 (0.36) SMN1; SMN2KDM4EPOLBTDP1ALOX15
SCHEMBL30885082 0.79 GPR35 (0.44) MCL1MEN1KMT2AGPR35SMN1; SMN2
SCHEMBL2866739 0.79 CYP1A2 (0.42) MCL1MEN1KMT2ANOTUMGPR35
SCHEMBL6854948 0.76 MAPT (0.34) MEN1KMT2ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL9686058 0.76 ALDH1A1 (0.46) MEN1KMT2AKDM4EL3MBTL1HPGD
Cyclopropane SCHEMBL11657479 0.74 CYP1A2 (0.38) MCL1MEN1KMT2ANOTUMSMN1; SMN2
SCHEMBL11468226 0.71 TDP1 (0.39) MEN1KMT2AKDM4EL3MBTL1POLB
SCHEMBL6766747 0.68 PKM (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104693355-B Terminal-modified conjugated diene-vinyl aromatic hydrocarbon copolymer and synthesis method thereof 奇美实业股份有限公司 2017-08-04 CN claimed
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
CN-113214465-A Poly (ethylene furan acid ester) copolymer and method 可口可乐公司 2021-08-06 CN disclosed
EP-3143068-B1 THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS ROQUETTE FRERES (FR) 2018-05-02 EP disclosed
EP-3143068-A1 THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS Roquette Frères (FR) 2017-03-22 EP disclosed
WO-2015170050-A1 THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS ROQUETTE FRERES (FR) 2015-11-12 WO disclosed
CN-101115711-A Diacylglycerol acyltransferase inhibitors HOFFMANN LA ROCHE (CH) 2008-01-30 CN disclosed
US-7317125-B2 Diacylglycerol acyltransferase inhibitors HOFFMAN-LA ROCHE INC. (US) 2008-01-08 US disclosed
EP-1848687-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) F. Hoffmann-Roche AG (CH) 2007-10-31 EP disclosed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060178532-A1 Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS, INC. 2006-08-10 US disclosed
WO-2006082010-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 WO disclosed
US-4303548-A Process for coating dispersed minute droplets with membrane MITSUBISHI PAPER MILLS, LTD. (JP) 1981-12-01 US disclosed
US-4097485-A HERBICIDES VELSICOL CHEMICAL CORPORATION (US) 1978-06-27 US disclosed
US-4086241-A Benzothiazolylimidazolidinone esters of furyl and thienyl substituted acids VELSICOL CHEMICAL CORPORATION (US) 1978-04-25 US disclosed
US-4061648-A HERBICIDES VELSICOL CHEMICAL CORPORATION (US) 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178532-A1 Diacylglycerol acyltransferase inhibitors DGAT2, DGAT1, LCAT MCL1 3215/4885MEN1 3463/4885KMT2A 1380/4885
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 MCL1 557/4885MEN1 3793/4885KMT2A 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.